HC Wainwright Boosts Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Disc Medicine in a report released on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($6.19) for the year, up from their prior estimate of ($6.64). HC Wainwright currently has a “Buy” rating and a $127.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.54) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2026 earnings at ($1.47) EPS, Q2 2027 earnings at ($1.87) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($0.86) EPS, FY2027 earnings at ($5.56) EPS, FY2028 earnings at ($4.01) EPS, FY2029 earnings at $0.78 EPS and FY2030 earnings at $6.23 EPS.

A number of other analysts have also recently weighed in on IRON. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday. Wells Fargo & Company increased their target price on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a research report on Tuesday, October 20th. Truist Financial raised their target price on shares of Disc Medicine from $83.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Finally, Guggenheim initiated coverage on shares of Disc Medicine in a research note on Monday. They issued a “buy” rating and a $132.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average price target of $124.18.

Disc Medicine Stock Performance

IRON stock opened at $81.26 on Tuesday. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -12.82 and a beta of 0.96. The firm has a 50-day simple moving average of $71.23 and a two-hundred day simple moving average of $70.97. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.10.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, CEO John Quisel sold 33,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 168,046 shares of company stock worth $13,191,034. 3.76% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Disc Medicine in the second quarter worth $180,502,000. Wellington Management Group LLP grew its holdings in shares of Disc Medicine by 0.3% during the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after buying an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock valued at $73,280,000 after buying an additional 735,300 shares during the last quarter. Opaleye Management Inc. grew its holdings in shares of Disc Medicine by 103.1% during the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock valued at $62,535,000 after buying an additional 434,000 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of Disc Medicine by 14.7% in the 1st quarter. Jennison Associates LLC now owns 610,382 shares of the company’s stock valued at $39,028,000 after acquiring an additional 78,303 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026, FY2027, and FY2028 to losses of $6.19, $5.56, and $4.01 per share, respectively, versus prior estimates of $6.64, $6.47, and $4.62. It also improved its Q4 2026 estimate to a $1.47 loss from a $1.74 loss. The analyst reaffirmed a Buy rating and $127 target, a constructive signal for shares. Disc Medicine analyst estimate updates
• Positive Sentiment: A separate report cited a $124.18 consensus price target, suggesting analysts see potential upside relative to the stock’s recent trading level. Disc Medicine consensus target price
• Negative Sentiment: HC Wainwright lowered its projected earnings for FY2029 to $0.78 per share from $1.03, and FY2030 to $6.23 from $7.34. These cuts temper the positive near-term revisions, though the forecasts still project a shift to profitability in 2029.

About Disc Medicine

Disc Medicine, Inc is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function.

The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.